Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 759 clinical trials
None
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

is not yet known whether gemtuzumab ozogamicin is more effective than standard supportive care in treating older patients who have acute myeloid leukemia. PURPOSE: This randomized phase II

monoclonal antibody therapy
cancer
myeloid leukemia
monoclonal antibodies
gemtuzumab ozogamicin
  • 30 views
  • 07 Nov, 2020
  • 2 locations
None
Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia

The treatment of CML and the expected survival has been revolutionised since the introduction of tyrosine kinase inhibitors (TKIs) such as nilotinib. Despite their effectiveness, these drugs will never totally remove CML affected cells from the body. In order to achieve this goal, and potentially enable CML patients to live …

basophils
interferon
lipase
chronic phase chronic myeloid leukemia
imatinib
  • 10 views
  • 07 Nov, 2020
  • 1 location
None
Bisantrene Combination for Resistant AML

An Open-label, Phase II, Two-stage, Study of Xantrene (Bisantrene) in combination with Fludarabine and Clofarabine as Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid

fludarabine
ejection fraction
clofarabine
carbon monoxide
  • 0 views
  • 30 Sep, 2021
  • 1 location
None
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein and Post-HCT Treatment With Mylotarg for Patients With CD33+ AML

This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).

blast cells
mylotarg
transplant conditioning
remission
residual tumor
  • 0 views
  • 19 Nov, 2021
  • 5 locations
None
Efficacy of G-CSF-Priming in Elderly AML Patients

Aim of the study is to compare the efficacy of intensive induction therapy with Cytarabine, Idarubicin and Etoposide (IdAV) given in parallel with (G-CSF priming) and followed by G-CSF versus the same IdAV chemotherapy only followed by G-CSF (without priming) in elderly patients with de novo AML, secondary AML and …

consolidation therapy
cytarabine
granulocyte colony stimulating factor
fludarabine
neoadjuvant therapy
  • 50 views
  • 07 Nov, 2020
  • 1 location
None
Targeted Dose-Escalated Intravenous Busulfan and Bolus Etoposide as Preparative Therapy for Patients With Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation

The study hypothesis is that higher dose intravenous busulfan can be delivered safely to AML patients undergoing autologous transplantation. If this hypothesis is true the investigators plan to examine in a future study whether higher-dose busulfan can improve overall survival following autologous transplantation for AML.

ara-c
busulfan
cytarabine
cell transplantation
  • 19 views
  • 07 Nov, 2020
  • 1 location
None
Intermittent Liposomal Amphotericin B Primary Prophylaxis

The purpose of this trial is to see which dose of liposomal amphotericin B is the safest when used as a preventer against invasive fungal infection in patients with acute leukaemia who are undergoing chemotherapy.

acute leukemia
  • 16 views
  • 07 Nov, 2020
  • 1 location
None
Study to Assess the Safety Tolerability and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia

This is one of the first studies of combination of Zarnestra plus Velcade in man. A primary objective of the study is therefore to assess the safety and tolerability of multiple doses of Zarnestra plus Velcade in patients with AML. New treatments for patients that are untreatable with intensive chemotherapy …

  • 14 views
  • 07 Nov, 2020
  • 1 location
None
Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML

myeloid leukemia other than acute promyelocytic leukemia - The feasibility will be evaluated in terms of toxicities, complete remission rate, duration of complete remission, disease

colony stimulating factor
cytarabine
remission
fludarabine
granulocyte colony stimulating factor
  • 23 views
  • 07 Nov, 2020
  • 1 location
None
FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML

myeloid leukemia other than acute promyelocytic leukemia

acute promyelocytic leukemia
idarubicin
induction chemotherapy
colony stimulating factor
cytarabine
  • 22 views
  • 07 Nov, 2020
  • 1 location